Capricor Deadline: CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm, a plaintiff-side investor rights firm, is reminding purchasers of Capricor Therapeutics (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 deadline to seek lead plaintiff status in a securities fraud class action already filed against the company. The complaint alleges Capricor changed the pre-specified statistical analysis plan for its Deramiocel cell therapy without FDA agreement before resubmitting the Biologics License Application, creating a substantial risk the agency finds the Duchenne muscular dystrophy data lack substantial evidence of effectiveness.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.